AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Related Articles
Selinexor May Confer PFS Benefit in TP53 Wild-Type Endometrial Cancer
David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.
Addressing Gaps in Education for Non–Clear Cell RCC
A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.
IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma
IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
NCI’s Clinical and Translational Data Commons Has Launched! | CBIIT
The NCI Cancer Research Data Commons has launched the Clinical and Translational Data Commons, a dedicated resource for NCI-funded clinical and translational data. Learn more…
Imaging at OHSU: Scientists use advanced imaging in the fight against cancer
At OHSU Knight Cancer Institute, patients are front of mind in drive toward cancer early detection, interventions.
High-density sampling reveals volume growth in human tumours
In growing cell populations such as cancer, mutations can serve as markers that allow tracking the past evolution from current samples. The genomic analysis of…
Health Volunteers Overseas
To improve the quality of medical care in developing countries, ASH has partnered with Health Volunteers Overseas (HVO), a nonprofit organization dedicated to improving global…
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18) | Journal of Clinical Oncology
PURPOSETo investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant chemotherapy has a benefit on progression-free survival (PFS),…
Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA
Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the…